Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 4Withdrawn 1

Sponsor Class

NIH 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Lymphoid 4Genitourinary 4Other hematologic neoplasm 3Sarcoma 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 2Neoplasms 2Extensive Stage Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × gossypol acetic acid × Thoracic × Clear all
NCT00773955 2014-05-12

R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
15 enrolled 7 charts
Thoracic

Small Cell Lung Carcinoma

NCT00544596 2014-04-02

R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
Other solid neoplasmThoracic

Extensive Stage Small Cell Lung Cancer

NCT00544960 2010-08-27

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

Ascenta Therapeutics

Phase 2 Completed
106 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00397293 2010-08-24

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Ascenta Therapeutics

Phase 1/2 Completed
36 enrolled
Thoracic

Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡